BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

10 5 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

04 5 2021 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast

03 5 2021 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperative De-escalation in the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

29 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting

26 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

31 3 2021 16:01:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia

15 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

11 3 2021 07:15:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

11 3 2021 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast

04 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation

03 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints June Bray to Board of Directors

01 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation

25 2 2021 07:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary

23 2 2021 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms

12 2 2021 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

04 2 2021 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease

05 1 2021 07:00:01 提供 Nasdaq GlobeNewswire